VICORE PHARMA AB
13Patents
12Active
13Granted
59Portfolio score
Filing activity: Nov 26, 2003 → Dec 20, 2023 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7652054B2 | Tricyclic compounds useful as angiotensin II agonists | Chemistry; Metallurgy | 4 | Expired |
| US11819494B2 | Treatment of idiopathic pulmonary fibrosis | Human Necessities | 3 | Active |
| US11654115B2 | Delayed release composition for peroral administration | Human Necessities | 3 | Active |
| US11844868B2 | Dry powder composition for peroral administration | Human Necessities | 3 | Active |
| US8124638B2 | Tricyclic compounds useful as angiotensin II agonists | Chemistry; Metallurgy | 2 | Active |
| US8835471B2 | Use of angiotensin II agonists | Chemistry; Metallurgy | 1 | Active |
| US8357710B2 | Bicyclic angiotensin II agonists | Chemistry; Metallurgy | 0 | Active |
| US12128029B2 | Treatment of idiopathic pulmonary fibrosis | Human Necessities | 0 | Active |
| US12121614B2 | Delayed release composition for peroral administration | Human Necessities | 0 | Active |
| US8067418B2 | Tricyclic angiotensin II agonists | Human Necessities | 0 | Active |
| US11123329B1 | Use of angiotensin II type 2 receptor agonist | Human Necessities | 0 | Active |
| US8080571B2 | Tricyclic angiotensin II agonists | Human Necessities | 0 | Active |
| US12213961B2 | Treatment of idiopathic pulmonary fibrosis | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.